High LARGE1 Expression May Predict Benefit from Adjuvant Chemotherapy in Resected Non-Small-Cell Lung Cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):425.
   Web of Science ®Google Scholar
• Travis WD. Pathology of lung cancer. Clin Chest Med. 2011;32(4):669–692. doi:10.1016/j.ccm.2011.08.005
   PubMed Web of Science ®Google Scholar
• Torre LA, Siegel RL, Jemal A. Lung cancer statistics. Adv Exp Med Biol. 2016;893:893. doi:10.1007/978-3-319-24223-1_1
   Web of Science ®Google Scholar
• Xue C, Hu Z, Jiang W, et al. National survey of the medical treatment status for non-small cell lung cancer (NSCLC) in China. Lung Cancer. 2012;77(2):371–375. doi:10.1016/j.lungcan.2012.04.014
   PubMed Web of Science ®Google Scholar
• Hung -J-J, Jeng W-J, Hsu W-H, Huang B-S, Wu Y-C. Time trends of overall survival and survival after recurrence in completely resected stage I non-small cell lung cancer. J Thorac Oncol. 2012;7(2):397–405. doi:10.1097/JTO.0b013e31823b564a
   Web of Science ®Google Scholar
• Su S, Scott WJ, Allen MS, et al. Patterns of survival and recurrence after surgical treatment of early stage non–small cell lung carcinoma in the ACOSOG Z0030 (ALLIANCE) trial. J Thorac Cardiovasc Surg. 2014;147(2):2. doi:10.1016/j.jtcvs.2013.10.001
   Web of Science ®Google Scholar
• Chen W, Zheng R, Zhang S, Zhao P, Zeng H, Zou X. Report of cancer incidence and mortality in China, 2010. Ann Transl Med. 2014;2(7):61. doi:10.3978/j.issn.2305-5839.2014.04.05
   PubMedGoogle Scholar
• Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell. 2015;28(6):690–714. doi:10.1016/j.ccell.2015.10.012
   PubMed Web of Science ®Google Scholar
• Arriagada R, Bergman B, Dunant A, Le Chevalier T. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350(4):351–360.
   PubMed Web of Science ®Google Scholar
• Waller D, Peake MD, Stephens RJ, et al. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg. 2004;26(1):173–182. doi:10.1016/j.ejcts.2004.03.041
   PubMed Web of Science ®Google Scholar
• Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non–small-cell lung cancer. N Engl J Med. 2005;352(25):2589–2597. doi:10.1056/NEJMoa043623
   PubMed Web of Science ®Google Scholar
• Douillard J-Y, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB–IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006;7(9):719–727. doi:10.1016/S1470-2045(06)70804-X
   PubMed Web of Science ®Google Scholar
• Strauss GM, Herndon JE, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non–small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol. 2008;26(31):5043–5051. doi:10.1200/JCO.2008.16.4855
   PubMed Web of Science ®Google Scholar
• Pignon J-P, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26(21):3552–3559. doi:10.1200/JCO.2007.13.9030
   PubMed Web of Science ®Google Scholar
• Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007;7(8):573–584. doi:10.1038/nrc2167
   PubMed Web of Science ®Google Scholar
• Inamori K, Hara Y, Willer T, et al. Xylosyl- and glucuronyltransferase functions of LARGE in α-dystroglycan modification are conserved in LARGE2. Glycobiology. 2013;23(3):295–302. doi:10.1093/glycob/cws152
   Web of Science ®Google Scholar
• de Bernabé DB-V, Inamori K-I, Yoshida-Moriguchi T, et al. Loss of α-dystroglycan laminin binding in epithelium-derived cancers is caused by silencing of LARGE. J Biol Chem. 2009;284(17):11279–11284. doi:10.1074/jbc.C900007200
   Web of Science ®Google Scholar
• Beltrán D, Anderson ME, Bharathy N, et al. Exogenous expression of the glycosyltransferase LARGE1 restores α-dystroglycan matriglycan and laminin binding in rhabdomyosarcoma. Skeletal Muscle. 2019;9(1):11. doi:10.1186/s13395-019-0195-0
   Web of Science ®Google Scholar
• Goldman MJ, Craft B, Hastie M, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020;38(6):675–678. doi:10.1038/s41587-020-0546-8
   PubMed Web of Science ®Google Scholar
• Győrffy B, Surowiak P, Budczies J, Lánczky A, Chellappan SP. Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS One. 2013;8(12):e82241. doi:10.1371/journal.pone.0082241
   PubMed Web of Science ®Google Scholar
• Tang H, Xiao G, Behrens C, et al. A 12-Gene Set Predicts Survival Benefits from Adjuvant Chemotherapy in Non–Small Cell Lung Cancer Patients. Clin Cancer Res. 2013;19(6):1577–1586. doi:10.1158/1078-0432.CCR-12-2321
   PubMed Web of Science ®Google Scholar
• Zhu C-Q, Ding K, Strumpf D, Zhu CQ, Ding K, Strumpf D, et al. Prognostic and Predictive Gene Signature for Adjuvant Chemotherapy in Resected Non–Small-Cell Lung Cancer. J Clin Oncol. 2010;28(29):4417–4424. doi:10.1200/JCO.2009.26.4325
   PubMed Web of Science ®Google Scholar
• Lung A, Shedden K, Taylor JM, et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med. 2008;14(8):822–827.
   Web of Science ®Google Scholar
• Cerami E, Gao J, Dogrusoz U, et al. The cBio Cancer Genomics Portal: an open platform for exploring multidimensional cancer genomics data: figure 1. Cancer Discov. 2012;2(5):401. doi:10.1158/2159-8290.CD-12-0095
   PubMed Web of Science ®Google Scholar
• Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1. doi:10.1126/scisignal.2004088
   PubMed Web of Science ®Google Scholar
• Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545. doi:10.1073/pnas.0506580102
   PubMed Web of Science ®Google Scholar
• Mootha VK, Lindgren CM, Eriksson K-F, et al. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003;34(3):267–273. doi:10.1038/ng1180
   PubMed Web of Science ®Google Scholar
• Akbani R, Ng PKS, Werner HMJ, et al. A pan-cancer proteomic perspective on The Cancer Genome Atlas. Nat Commun. 2014;5(1):3887. doi:10.1038/ncomms4887
   PubMed Web of Science ®Google Scholar
• Barresi R. Dystroglycan: from biosynthesis to pathogenesis of human disease. J Cell Sci. 2006;119(2):199–207. doi:10.1242/jcs.02814
   Web of Science ®Google Scholar
• Yamada H, Denzer AJ, Hori H, et al. Dystroglycan is a dual receptor for agrin and laminin-2 in Schwann cell membrane. J Biol Chem. 1996;271(38):23418–23423. doi:10.1074/jbc.271.38.23418
   PubMed Web of Science ®Google Scholar
• Kanagawa M, Saito F, Kunz S, et al. Molecular recognition by LARGE is essential for expression of functional dystroglycan. Cell. 2004;117(7):953–964. doi:10.1016/j.cell.2004.06.003
   PubMed Web of Science ®Google Scholar
• Kunz S, Sevilla N, McGavern DB, Campbell KP, Oldstone MBA. Molecular analysis of the interaction of LCMV with its cellular receptor α-dystroglycan. J Cell Biol. 2001;155(2):301–310. doi:10.1083/jcb.200104103
   Web of Science ®Google Scholar
• Gee SH, Montanaro F, Lindenbaum MH, Carbonetto S. Dystroglycan-α, a dystrophin-associated glycoprotein, is a functional agrin receptor. Cell. 1994;77(5):675–686. doi:10.1016/0092-8674(94)90052-3
   Web of Science ®Google Scholar
• Talts JF, Andac Z, Göhring W, Brancaccio A, Timpl R. Binding of the G domains of laminin α1 and α2 chains and perlecan to heparin, sulfatides, α-dystroglycan and several extracellular matrix proteins. EMBO J. 1999;18(4):863–870. doi:10.1093/emboj/18.4.863
   PubMed Web of Science ®Google Scholar
• Wright KM, Lyon KA, Leung H, Leahy DJ, Ma L, Ginty DD. Dystroglycan organizes axon guidance cue localization and axonal pathfinding. Neuron. 2012;76(5):931–944. doi:10.1016/j.neuron.2012.10.009
   Web of Science ®Google Scholar
• Sgambato A, Brancaccio A. The dystroglycan complex: from biology to cancer. J Cell Physiol. 2005;205(2):163–169. doi:10.1002/jcp.20411
   Web of Science ®Google Scholar
• Sgambato A, Di Salvatore MA, De Paola B, et al. Analysis of dystroglycan regulation and functions in mouse mammary epithelial cells and implications for mammary tumorigenesis. J Cell Physiol. 2006;207(2):520–529. doi:10.1002/jcp.20600
   Web of Science ®Google Scholar
• Losasso C, Di Tommaso F, Sgambato A, et al. Anomalous dystroglycan in carcinoma cell lines. FEBS Lett. 2000;484(3):194–198. doi:10.1016/S0014-5793(00)02157-8
   Web of Science ®Google Scholar
• Calogero A, Pavoni E, Gramaglia T, et al. Altered expression of alpha-dystroglycan subunit in human gliomas. Cancer Biol Ther. 2006;5(4):441–448. doi:10.4161/cbt.5.4.2546
   PubMed Web of Science ®Google Scholar
• Sgambato A, Camerini A, Faraglia B, et al. Increased expression of dystroglycan inhibits the growth and tumorigenicity of human mammary epithelial cells. Cancer Biol Ther. 2004;3(10):967–975. doi:10.4161/cbt.3.10.1132
   PubMed Web of Science ®Google Scholar
• Sgambato A, Migaldi M, Montanari M, et al. Dystroglycan expression is frequently reduced in human breast and colon cancers and is associated with tumor progression. Am J Pathol. 2003;162(3):849–860. doi:10.1016/S0002-9440(10)63881-3
   Web of Science ®Google Scholar
• Sgambato A, De Paola B, Migaldi M, et al. Dystroglycan expression is reduced during prostate tumorigenesis and is regulated by androgens in prostate cancer cells. J Cell Physiol. 2007;213(2):528–539. doi:10.1002/jcp.21130
   Web of Science ®Google Scholar
• Coco C, Zannoni GF, Caredda E, et al. Increased expression of CD133 and reduced dystroglycan expression are strong predictors of poor outcome in colon cancer patients. J Exp Clin Cancer Res. 2012;31(1):71. doi:10.1186/1756-9966-31-71
   Web of Science ®Google Scholar
• Sgambato A, Tarquini E, Resci F, et al. Aberrant expression of α-dystroglycan in cervical and vulvar cancer. Gynecol Oncol. 2006;103(2):397–404. doi:10.1016/j.ygyno.2006.03.059
   Web of Science ®Google Scholar
• Moon YW, Rha SY, Zhang X, et al. Increments of α-dystroglycan expression in liver metastasis correlate with poor survival in gastric cancer. J Surg Oncol. 2009;100(6):459–465. doi:10.1002/jso.21347
   Web of Science ®Google Scholar
• Zhang H-Z, Xia X-Y, Zhu F, Shen H, Song K, Shang Z-J. Correlation of deregulated like-acetylglucosaminyl transferase and aberrant α-dystroglycan expression with human tongue cancer metastasis. J Oral Maxillofac Surg. 2014;72(6):1106–1118. doi:10.1016/j.joms.2013.12.031
   Web of Science ®Google Scholar
• Jiang X, Rieder S, Giese NA, Friess H, Michalski CW, Kleeff KJ. Reduced α-dystroglycan expression correlates with shortened patient survival in pancreatic cancer. J Surg Res. 2011;171(1):120–126. doi:10.1016/j.jss.2009.11.730
   Web of Science ®Google Scholar
• Jing J, Lien CF, Sharma S, Rice J, Brennan PA, Górecki DC. Aberrant expression, processing and degradation of dystroglycan in squamous cell carcinomas. Eur J Cancer. 2004;40(14):2143–2151. doi:10.1016/j.ejca.2004.05.018
   Web of Science ®Google Scholar
• Sgambato A, Camerini A, Amoroso D, et al. Expression of dystroglycan correlates with tumor grade and predicts survival in renal cell carcinoma. Cancer Biol Ther. 2007;6(12):1840–1846. doi:10.4161/cbt.6.12.4983
   PubMed Web of Science ®Google Scholar
• Henry MD, Cohen MB, Campbell KP. Reduced expression of dystroglycan in breast and prostate cancer. Hum Pathol. 2001;32(8):791–795. doi:10.1053/hupa.2001.26468
   Web of Science ®Google Scholar
• Shen JG, Xu CY, Li X, et al. Dystroglycan is associated with tumor progression and patient survival in gastric cancer. Pathol Oncol Res. 2012;18(1):79–84. doi:10.1007/s12253-011-9419-2
   Web of Science ®Google Scholar
• Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non–small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355(10):983–991. doi:10.1056/NEJMoa060570
   PubMed Web of Science ®Google Scholar
• Sève P, Lai R, Ding K, Sève P, Lai R, Ding K, et al. Class III β-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non–small cell lung cancer: analysis of NCIC JBR.10. Clin Cancer Res. 2007;13(3):994–999. doi:10.1158/1078-0432.CCR-06-1503
   PubMed Web of Science ®Google Scholar
• Reiman T, Lai R, Veillard AS, et al. Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials. Ann Oncol. 2012;23(1):86–93. doi:10.1093/annonc/mdr033
   PubMed Web of Science ®Google Scholar
• Friboulet L, Olaussen KA, Pignon J-P, et al. ERCC1 isoform expression and DNA repair in non–small-cell lung cancer. N Engl J Med. 2013;368(12):1101–1110. doi:10.1056/NEJMoa1214271
   PubMed Web of Science ®Google Scholar
• Olaussen KA, Postel-Vinay S. Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape. Ann Oncol. 2016;27(11):2004–2016. doi:10.1093/annonc/mdw321
   PubMed Web of Science ®Google Scholar
• Wallerek S, Sørensen JB. Biomarkers for efficacy of adjuvant chemotherapy following complete resection in NSCLC stages I–IIIA. Eur Respir Rev. 2015;24(136):340–355. doi:10.1183/16000617.00005814
   Google Scholar
• Seymour L, Le Teuff G, Brambilla E, et al. LACE-Bio: validation of predictive and/or prognostic immunohistochemistry/histochemistry-based biomarkers in resected non–small-cell lung cancer. Clin Lung Cancer. 2019;20(2):2. doi:10.1016/j.cllc.2018.10.001
   Web of Science ®Google Scholar
• Petersen OW, Rønnov-Jessen L, Howlett AR, Bissell MJ. Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells. Proc Natl Acad Sci U S A. 1992;89(19):9064–9068. doi:10.1073/pnas.89.19.9064
   PubMed Web of Science ®Google Scholar